NCT01301963 · OUTCOME

Percentage of Patients Achieving Target Goal CD34+ Cells Dose

Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide · Source last updated 2014-08-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: In =< 5 days of leukaphereses

Analysis population: Due to low enrollment (10% of anticipated participants), no analysis is being done on data collected in this study

Groups in this outcome

Arm I: Control

Patients receive G-CSF SC QD on days 1-4. filgrastim: Given SC

Arm II: Experimental

Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8. plerixafor: Given SC filgrastim: Given SC

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm I: Control	0
Arm II: Experimental	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
group Id
OG001
value
0
units
Participants

groups

description
Patients receive G-CSF SC QD on days 1-4. filgrastim: Given SC
id
OG000
title
Arm I: Control
description
Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8. plerixafor: Given SC filgrastim: Given SC
id
OG001
title
Arm II: Experimental

population Description

Due to low enrollment (10% of anticipated participants), no analysis is being done on data collected in this study

reporting Status

POSTED

time Frame

In =< 5 days of leukaphereses

title

Percentage of Patients Achieving Target Goal CD34+ Cells Dose

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice